NMR IN DRUG DISCOVERY

NMR has become a valuable screening tool for analysing the binding of ligands to protein targets. Furthermore, NMR can provide structural information on protein–ligand interactions to aid in the optimization of weak-binding hits into high-affinity leads. Methods for detecting binding fall into two main categories: those that monitor NMR signals from the ligand and those that monitor NMR signals from the protein. Experiments that monitor the ligand exploit the large differences in the rates of rotational and translational motions of a small molecule in the free state relative to when it is bound to a macromolecules. The consequent effects on NMR properties, such as transverse and longitudinal relaxation times, are indicative of ligand binding. Experiments that monitor the ligand have the advantages of requiring only small quantities of unlabelled protein, and also allowing several compounds to be studied simultaneously. Experiments that monitor the protein, such as chemical-shift mapping, usually require labelled protein. However, coupled with resonance assignments, they can provide valuable information on the location of binding sites and the nature of the interactions that is not given by experiments that monitor the ligand. In SAR by NMR, ligand binding is detected by chemical-shift mapping using a labelled protein target. In this way, small molecules that bind to two distinct sites on the protein are identified. Structural information on the binding modes and site positions is then used to aid the discovery of high-affinity compounds in which the two small-molecule fragments are linked. SHAPES is a strategy in which ligand binding is assessed by observing signals from the ligand. Hits from a screen of a fairly small but diverse library of low-molecular weight scaffolds against an unlabelled protein target are optimized into high-affinity compounds by iterative synthetic modification and re-screening. NMR-SOLVE exploits the fact that large families of proteins have adjacent binding sites, one of which is conserved throughout the family. It uses selective labelling of residues around the conserved binding site to guide the synthesis of high-affinity bi-ligand inhibitors, one part of which binds in the conserved binding site, and the other which binds in the adjacent site to give specificity. NMR has become a valuable screening tool for analysing the binding of ligands to protein targets. Furthermore, NMR can provide structural information on protein–ligand interactions to aid in the optimization of weak-binding hits into high-affinity leads. Methods for detecting binding fall into two main categories: those that monitor NMR signals from the ligand and those that monitor NMR signals from the protein. Experiments that monitor the ligand exploit the large differences in the rates of rotational and translational motions of a small molecule in the free state relative to when it is bound to a macromolecules. The consequent effects on NMR properties, such as transverse and longitudinal relaxation times, are indicative of ligand binding. Experiments that monitor the ligand have the advantages of requiring only small quantities of unlabelled protein, and also allowing several compounds to be studied simultaneously. Experiments that monitor the protein, such as chemical-shift mapping, usually require labelled protein. However, coupled with resonance assignments, they can provide valuable information on the location of binding sites and the nature of the interactions that is not given by experiments that monitor the ligand. In SAR by NMR, ligand binding is detected by chemical-shift mapping using a labelled protein target. In this way, small molecules that bind to two distinct sites on the protein are identified. Structural information on the binding modes and site positions is then used to aid the discovery of high-affinity compounds in which the two small-molecule fragments are linked. SHAPES is a strategy in which ligand binding is assessed by observing signals from the ligand. Hits from a screen of a fairly small but diverse library of low-molecular weight scaffolds against an unlabelled protein target are optimized into high-affinity compounds by iterative synthetic modification and re-screening. NMR-SOLVE exploits the fact that large families of proteins have adjacent binding sites, one of which is conserved throughout the family. It uses selective labelling of residues around the conserved binding site to guide the synthesis of high-affinity bi-ligand inhibitors, one part of which binds in the conserved binding site, and the other which binds in the adjacent site to give specificity.